The aryl hydrocarbon receptor (AhR) as a breast cancer drug target

Area of Science:

• Oncology
• Molecular Biology
• Pharmacology

Background:

• Breast cancer is a leading cause of death in women globally, with metastatic and triple-negative subtypes lacking effective treatments.
• The aryl hydrocarbon receptor (AhR), typically involved in metabolizing foreign compounds, is a potential therapeutic target for breast cancer.
• AhR ligands, both external and internal, can act as agonists or antagonists, influencing cancer cell growth.

Purpose of the Study:

• To review current literature on aryl hydrocarbon receptor (AhR) targeting for breast cancer treatment.
• To explore advances in manipulating the AhR pathway for therapeutic benefit.
• To assess the potential of AhR-targeted therapies for incurable breast cancer, including triple-negative phenotypes.

Main Methods:

• Literature review of studies investigating aryl hydrocarbon receptor (AhR) ligands and their effects on breast cancer cells.
• Analysis of research on the cytosolic-to-nuclear signaling pathway of AhR.
• Examination of clinical trial data for AhR-targeting drugs, such as aminoflavone.

Main Results:

• Agonistic AhR ligands demonstrate potent and selective growth inhibition in various cancer cell lines.
• Aminoflavone, an AhR ligand, has advanced to Phase I clinical trials for breast cancer patients.
• The study highlights promising strategies for hijacking the AhR pathway in breast cancer therapy.

Conclusions:

• The aryl hydrocarbon receptor (AhR) pathway presents a promising target for novel breast cancer treatments.
• Targeting AhR offers potential for managing aggressive and currently untreatable breast cancer subtypes.
• Further research into AhR modulation could lead to effective therapeutic interventions for breast cancer.